Novartis (NVS) Stock Surges 5% Following Positive Multiple Sclerosis Drug Trial Results

Novartis (NVS) stock surged 5% after remibrutinib succeeded in two Phase 3 MS trials, outperforming Sanofi's Aubagio despite rap-cel therapy concerns.

The post Novartis (NVS) Stock Surges 5% Following Positive Multiple Sclerosis Drug Trial Results appeared first on Blockonomi.